Skip to content
Catalyst
Search

Papers/PMID:17617901

Effects of high doses of selenium, as sodium selenite, in septic shock: a placebo-controlled, randomized, double-blind, phase II study.

Critical care (London, England)2007The record

2 findings · 1 compound · 2 endpoints · 2 null

What it reported

How to read these marks

Every finding here is a null result.

What did not

2 findings

  • selenium atom — no detected effect on hospital length of stay

    Evidence strength: moderate.FindingNull result
    “The median (interquartile range) ICU and hospital lengths of stay did not differ between the placebo and selenium groups (18 (10–31) days versus 21 (7–40) days, respectively, for the ICU length of stay; P = 0.836; and 33 (11–51) days versus 25 (7–68) days, respectively, for the hospital length of stay; P = 0.704).”
    Quoted verbatim from Effects of high doses of selenium, as sodium selenite, in septic shock: a placebo-controlled, randomized, double-blind, phase II study..
    Study
    RCT
    Duration
    10 days
    Dose
    Selenium as sodium selenite, 4,000 μg on day 1 then 1,000 μg/day for nine days, continuous intravenous infusion
    Population
    Adults with severe septic shock and documented infection requiring mechanical ventilation, seven French ICUs; selenium (sodium selenite) versus matching placebo

    Effects of high doses of selenium, as sodium selenite, in septic shock: a placebo-controlled, randomized, double-blind, phase II study.2007PMID:1761790110.1186/cc5960Industry fundedPermalink

  • selenium atom — no detected effect on intensive care unit length of stay

    Evidence strength: limited.FindingNull resultreplicated ×1
    “The median (interquartile range) ICU and hospital lengths of stay did not differ between the placebo and selenium groups (18 (10–31) days versus 21 (7–40) days, respectively, for the ICU length of stay; P = 0.836; and 33 (11–51) days versus 25 (7–68) days, respectively, for the hospital length of stay; P = 0.704).”
    Quoted verbatim from Effects of high doses of selenium, as sodium selenite, in septic shock: a placebo-controlled, randomized, double-blind, phase II study..
    Study
    RCT
    Duration
    10 days
    Dose
    Selenium as sodium selenite, 4,000 μg on day 1 then 1,000 μg/day for nine days, continuous intravenous infusion
    Population
    Adults with severe septic shock and documented infection requiring mechanical ventilation, seven French ICUs; selenium (sodium selenite) versus matching placebo

    Effects of high doses of selenium, as sodium selenite, in septic shock: a placebo-controlled, randomized, double-blind, phase II study.2007PMID:1761790110.1186/cc5960Industry fundedPermalink